- Home
- INCR vs SLS Comparison
INCR vs SLS Comparison
Compare INCR & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCR
- SLS
- Stock Information
- Founded
- INCR 1994
- SLS 2012
- Country
- INCR Israel
- SLS United States
- Employees
- INCR N/A
- SLS N/A
- Industry
- INCR Biotechnology: Pharmaceutical Preparations
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- INCR Health Care
- SLS Health Care
- Exchange
- INCR Nasdaq
- SLS Nasdaq
- Market Cap
- INCR 76.7M
- SLS 89.6M
- IPO Year
- INCR N/A
- SLS N/A
- Fundamental
- Price
- INCR $1.38
- SLS $1.09
- Analyst Decision
- INCR
- SLS
- Analyst Count
- INCR 0
- SLS 0
- Target Price
- INCR N/A
- SLS N/A
- AVG Volume (30 Days)
- INCR 10.9K
- SLS 811.7K
- Earning Date
- INCR 04-08-2025
- SLS 05-13-2025
- Dividend Yield
- INCR N/A
- SLS N/A
- EPS Growth
- INCR N/A
- SLS N/A
- EPS
- INCR N/A
- SLS N/A
- Revenue
- INCR $72,420,918.00
- SLS N/A
- Revenue This Year
- INCR N/A
- SLS N/A
- Revenue Next Year
- INCR $39.30
- SLS N/A
- P/E Ratio
- INCR N/A
- SLS N/A
- Revenue Growth
- INCR N/A
- SLS N/A
- 52 Week Low
- INCR $1.17
- SLS $0.77
- 52 Week High
- INCR $3.72
- SLS $1.84
- Technical
- Relative Strength Index (RSI)
- INCR 28.88
- SLS 40.56
- Support Level
- INCR $1.36
- SLS $1.13
- Resistance Level
- INCR $1.49
- SLS $1.25
- Average True Range (ATR)
- INCR 0.06
- SLS 0.07
- MACD
- INCR -0.01
- SLS -0.01
- Stochastic Oscillator
- INCR 4.67
- SLS 17.39
About INCR Intercure Ltd.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. The products are distributed to hospitals, pharmacies, research, and government organizations. The company has two segments namely: Cannabis segment and Biomed segment, out of which it derives maximum revenue from Cannabis segment.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.